IgA Nephropathy Causes
IgA Nephropathy Causes
The cause of IgA nephropathy is an antibody that is made in the wrong shape, in the wrong quantity, at the body's mucosal surfaces, and ends up lodged in the kidney's filtering units. This page sets out what that mechanism is, who it happens to, how much of it is genetic, when the deposition is secondary to another disease, and — separately — which factors make an established disease progress.
The molecule: an antibody with incomplete sugar chains
The mechanism is understood well enough to explain the disease's behaviour, which is unusual for a glomerular disease and useful for a patient trying to make sense of it. Immunoglobulin A comes in two forms, and the one involved here, IgA1, has a hinge region studded with sugar molecules. In IgA nephropathy a portion of the IgA1 produced is galactose-deficient: the sugar chains on that hinge are incomplete.
Two things follow. The incomplete hinge exposes a structure the immune system does not recognise as self, so the body makes antibodies — IgG and IgA — against its own IgA1. Those pair up into immune complexes that are too large to be cleared efficiently, and they circulate until they lodge in the mesangium of the glomerulus, where the filter's scaffolding catches them. The deposited complexes activate complement and attract inflammatory cells, and the filter leaks.
The third part explains why the disease flares with infections. The IgA1 comes from immune tissue at mucosal surfaces — tonsils, adenoids, airway and gut lining. An infection there is a stimulus to produce more of it, so each throat infection can bring a fresh wave of complexes and a fresh episode of visible haematuria. That is why the blood appears with the sore throat rather than weeks later.
One implication is worth drawing out, because it is the basis of the newest treatments. If the abnormal antibody is made in the gut-associated immune tissue, then the gut is a legitimate place to aim a treatment at — which is exactly what targeted-release budesonide does. The mechanism on this page is not abstract; it is what the treatment page's disease-specific medicines were built on.
Who develops it, and when
The typical patient is a young adult — most diagnoses fall between the teens and the forties, peaking in the second and third decades — and is more often male than female. It is the most common primary glomerular disease found on biopsy worldwide. A new diagnosis after middle age is less common and raises the question of a secondary cause.
| Factor | What is observed | How much it should worry you |
|---|---|---|
| Age | Presentation in the second to fourth decade is typical; diagnosis in later life is possible but raises the question of a secondary cause | Not modifiable, and not a predictor on its own. Later onset does mean a secondary cause should be looked for more carefully |
| Sex | More frequent in men, in whom progression is also somewhat more common | One input into risk, not a determinant of an individual outcome |
| Population and ancestry | Found more often on biopsy in East and South-East Asia than in some other regions | Reflects both genetic tendency and how intensively urine abnormalities are investigated |
| Family history | First-degree relatives affected more often than chance would predict | Worth mentioning to the clinician and worth a urine test in a relative with unexplained haematuria; not a reason to screen an asymptomatic family |
| Mucosal infection load | Episodes cluster around throat, sinus, chest and gut infections | Triggers episodes rather than causing the disease; treating infections promptly is sensible but does not prevent the disease |
| Coeliac disease and liver disease | Both are established associations, and both are treatable | The most actionable items on this page, which is why both are screened for |
The question behind this table is usually "why me", and the honest answer is that we can describe the mechanism and the associations without being able to point to a cause in an individual. That is not evasion; it is the actual state of knowledge, and it is a more useful answer than a plausible-sounding one invented to fill the gap.
How much of it is inherited
IgA nephropathy is not a Mendelian inherited disease. There is no single gene, no predictable pattern of transmission, and no test that tells a relative whether they will develop it. What does exist is a polygenic tendency: large studies have identified many common genetic variants, several of which affect mucosal immunity, the handling of infections and the risk of inflammatory bowel disease, and which together shift the probability rather than determine it.
Familial clustering is real but partial. A first-degree relative with the disease raises the probability, and families with several affected members are described — though some apparent familial cases turn out, on investigation, to be a different inherited condition with similar-looking urine.
The practical advice is correspondingly modest. There is no indication to screen asymptomatic relatives. A relative with persistent microscopic haematuria found on a routine test should have it properly evaluated — urine microscopy and a protein measurement — rather than being told it runs in the family. And a person with the disease who is planning a family can be told that the risk to their children is not zero but is not high enough to be a reason to change that plan.
When the deposition is secondary to another disease
Sometimes the IgA in the mesangium is not the disease but the kidney's record of another one. Recognising this matters because the treatment then belongs to the other disease.
| Underlying condition | How it leads to IgA deposition | What changes when it is found |
|---|---|---|
| Chronic liver disease, particularly cirrhosis | The liver clears IgA complexes from the circulation; when it cannot, they deposit in the kidney | The kidney management remains supportive and immune suppression is generally not the answer |
| Coeliac disease | Gluten-driven mucosal immune activation with production of the abnormal antibody | A gluten-free diet is the treatment, and in some patients the only one needed |
| Inflammatory bowel disease | Chronic intestinal inflammation driving the same mucosal antibody response | Controlling the bowel disease usually settles the kidney findings |
| Chronic infection, including viral hepatitis and HIV | Persistent antigenic stimulation driving complex formation | Treat the infection first; immune therapy is deferred until it is controlled |
| IgA vasculitis | The same antibody depositing in skin, gut, joints and kidney | A systemic disease treated as one, with kidney involvement graded by the same biopsy logic |
| A medicine or a supplement | A drug-induced immune response with IgA deposition | Withdrawal, which costs nothing and occasionally resolves the picture entirely |
The screen for these is blood tests, a medicine review and a careful history — cheap, quick and non-invasive. It is described in full on the diagnosis page, and it is one of the three things our record review checks before anything else is discussed.
What makes an established disease progress
Everything above is about why the disease appears. This section is about something different: given that a person has it, what determines whether it stays indolent or takes the kidney. The two lists barely overlap, which is why they are separated.
| Factor | What it does | Whether it is modifiable |
|---|---|---|
| Persistent proteinuria | The single strongest modifiable driver of progressive scarring | Yes — this is what blood pressure medicines, SGLT2 inhibitors and salt restriction act on |
| Raised blood pressure | Raises pressure inside the filter and accelerates scarring; both cause and consequence | Yes, and the most rewarding target in the whole disease |
| The extent of scarring on the biopsy | Tubular atrophy and interstitial fibrosis predict the outcome better than anything else | No — which is why finding the disease before this develops is the entire point of screening |
| Regular anti-inflammatory painkiller use | Reduces blood flow to the kidney and adds an avoidable injury on top of the disease | Yes, and the most commonly missed one because the medicines are bought without a prescription |
| Sodium intake | Raises blood pressure, increases proteinuria and blunts the effect of the medicines that treat both | Yes, though it is the hardest to change because most of it arrives in food someone else cooked |
| Repeated dehydration and acute illness | Each episode of acute injury on a scarred kidney leaves a permanent step down in function | Partly — hydration during illness and exertion, and prompt treatment of infections |
| Smoking and uncontrolled cardiovascular risk | Competes with the kidney disease as a cause of harm, and accelerates it directly | Yes, and it is the same work as the supportive care described on the treatment page |
| Weight gain and metabolic syndrome | Increases proteinuria and blood pressure, and adds cardiovascular risk | Yes, through the ordinary routes, at the ordinary pace |
The way to read this table is to notice that the two strongest drivers are also the two most treatable, and that the strongest predictor of all — established scarring — is the one nobody can do anything about. That asymmetry is the whole argument for the follow-up described on the prevention page: the disease is slow enough that there is time to act on the modifiable half, provided someone is actually measuring it.